The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 SciSparc Ltd. , a specialty clinical-stage pharmaceutical. | May 2, 2023
SciSparc (SPRC) Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer s Disease and Agitation streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Anavex 2-73/blarcamesine at high concentrations in early Alzheimer s disease leads to improvements in cognition. Click here to see our take on AVXL stock.
Biogen's Lecanemab only slows down the progression of Alzheimer's disease in APOE4 carriers and is suspected of causing deaths. Click for more on BIIB.